760,590 Works

Église de St. Paul à Londres. Détails. Pl. 2

Frei zum Herunterladen

Château de Chambord. Cour

Frei zum Herunterladen

Pyramide de Papantla. Méxique

Frei zum Herunterladen

Cathédrale de Gisors. Partie centrale de Façade

Frei zum Herunterladen

Église de St. Paul-St. Louis à Paris. France

Frei zum Herunterladen

Fort de St. André à Venise. Italie

Frei zum Herunterladen

Tombeau des cardinaux d'Amboise, à Rouen

Frei zum Herunterladen

Château de Chambord. France

Frei zum Herunterladen

Basilique de St. Pierre, à Rome. Plan

Frei zum Herunterladen

Cathédrale de Gisors. Détails [2]

Frei zum Herunterladen

Hôtel de Ville, à Cologne. Détails, Pl. II

Frei zum Herunterladen

Église du rédempteur à Venise. Italie

Frei zum Herunterladen

Château de Chambord. Détails, Pl. I

Frei zum Herunterladen

Château d'Azai-le-Rideau. Détails Pl. 2

Frei zum Herunterladen

Additional file 5: of Predict drug sensitivity of cancer cells with pathway activity inference

, , Michael Zimmermann, Andrej Bugrim & Jean-Pierre Kocher
Pathway map for anti-apoptotic action of ErbB2 in breast cancer. (PNG 1088 kb)

Additional file 5: of GenESysV: a fast, intuitive and scalable genome exploration open source tool for variants generated from high-throughput sequencing projects

Mohammad Zia, Paul Spurgeon, Adrian Levesque, Thomas Furlani &
Figure S2. VCF data importing times for input files with a fixed number of samples but an increasing number of variants. The VEP annotated 1000 Genomes Project Phase3 VCF file is used as input to create a series of VCF files to include the first 10, 20, 30, 40, 50, 60 and 70 million variants. These files (including the full VCF file containing the 85 million variants) are used as inputs for benchmarking data importation....

Additional file 8: of GenESysV: a fast, intuitive and scalable genome exploration open source tool for variants generated from high-throughput sequencing projects

Mohammad Zia, Paul Spurgeon, Adrian Levesque, Thomas Furlani &
Figure S5. Comparison of Elasticsearch index creation time between different Java Virtual Machine heap sizes. (TIFF 9492 kb)

05510049.jpg

05510074.jpg

05510175.jpg

Additional file 9: of Tracking of voluntary exercise behaviour over the lifespan

Matthijs Zee, Denise Mee, Meike Bartels &
Between-domain heatmaps.tif; Between-domain tracking coefficient heatmaps of exercise domains at baseline and total volume of exercise at follow-up. (TIF 23290 kb)

Additional file 2: of PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis

Lin Tuo, Jin Xiang, , , Hua Tang, Li Liang, Jie Xia, Yuan Hu, , , Kai Wang & Ni Tang
PCK1 supresses Huh7 cells proliferation. (JPG 2932 kb)

MOESM7 of CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death

Alexander Chung, Tina Leisner, Gabrielle Dardis, Marissa Bivins, Alana Keller & Leslie Parise
Additional file 7: Figure S6. CIB1 depletion may upregulate TRAIL-R1/R2 and IGF-1R expression in docetaxel-resistant TNBC cells. CIB1 depletion potentiates TRAIL-induced cell death in docetaxel-resistant MDA-436 cells potentially via upregulation of both TRAIL-R1 and â R2. a) Dose-response of docetaxel-induced cell death in parental (MDA-436-PR) versus docetaxel-resistant (MDA-436-DCXR) TNBC cells over 48 hr confirms resistance in MDA-436-DCXR cells. Cell death was quantified using trypan blue exclusion assay. Data represents means +/- SD (n=2). FACS analysis...

Additional file 5: of PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis

Lin Tuo, Jin Xiang, , , Hua Tang, Li Liang, Jie Xia, Yuan Hu, , , Kai Wang & Ni Tang
PCK1 retards G1/S phase transition via AMPK phosphorylation. (JPG 4500 kb)

Additional file 2: of Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer

, , , Kyung Ran Park & Chang Geol Lee
Figure S1. Survival outcomes according to the MTV change. Progression-free survival (A) and overall survival (B) of patients according to the metabolic tumor volume (MTV) reduction ratio (mid-treatment MTV-to-pretreatment MTV). Responders were patients with MTV reduction ratios â ¤1.14, while non-responders were patients with MTV reduction ratios >â 1.14. (TIF 204 kb)

Registration Year

  • 2019
    760,590

Resource Types

  • Image
    760,590